Vontobel Holding Ltd. Trims Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Vontobel Holding Ltd. decreased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 12.0% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,951 shares of the medical equipment provider’s stock after selling 675 shares during the quarter. Vontobel Holding Ltd.’s holdings in Lantheus were worth $543,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC raised its holdings in Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 208 shares during the period. Fidelis Capital Partners LLC purchased a new stake in shares of Lantheus during the first quarter worth about $34,000. FinTrust Capital Advisors LLC raised its stake in Lantheus by 53.6% during the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock valued at $41,000 after purchasing an additional 232 shares during the period. Nkcfo LLC purchased a new position in Lantheus in the 2nd quarter worth approximately $47,000. Finally, UMB Bank n.a. boosted its stake in Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 126 shares during the period. Institutional investors own 99.06% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on LNTH shares. B. Riley lifted their price objective on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Leerink Partners lifted their price target on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Thursday, July 11th. Truist Financial dropped their price objective on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Redburn Atlantic started coverage on Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price on the stock. Finally, JMP Securities reduced their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Lantheus has an average rating of “Moderate Buy” and a consensus target price of $126.00.

Insider Transactions at Lantheus

In related news, Director Gerard Ber sold 15,500 shares of the business’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares in the company, valued at $2,047,402.08. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, President Paul Blanchfield sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the transaction, the president now directly owns 98,980 shares of the company’s stock, valued at approximately $9,540,682.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gerard Ber sold 15,500 shares of Lantheus stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the sale, the director now directly owns 21,221 shares of the company’s stock, valued at $2,047,402.08. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 27,981 shares of company stock worth $2,689,156. 1.50% of the stock is currently owned by company insiders.

Lantheus Trading Down 4.0 %

Shares of LNTH opened at $112.08 on Tuesday. The company’s fifty day simple moving average is $106.11 and its 200-day simple moving average is $91.74. The company has a market cap of $7.77 billion, a P/E ratio of 17.11 and a beta of 0.50. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm had revenue of $394.10 million during the quarter, compared to analysts’ expectations of $382.12 million. During the same period last year, the company earned $1.40 earnings per share. The business’s revenue for the quarter was up 22.5% compared to the same quarter last year. As a group, analysts expect that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.